Back to search

Article

Therapeutic Combinations in Mild or Moderate COVID-19 to Reduce Nasopharyngeal Carriage of SARS-CoV-2 and Prevent Severe COVID-19 in Côte D’Ivoire: A Pragmatic Phase IIb Randomized Controlled Clinical Trial. The ANRS COV01 INTENSE-COV Trial

2022-10-10

Abstract excerpt

Background: Observational studies suggest a reduction in fatal or severe COVID-19 disease with the use of ACE2 inhibitors and statins.<br><br>Methods: This was a randomized controlled tree-arm open label trial evaluating the benefits of adding telmisartan (TLM) or atorvastatin (ATV) to lopinavir boosted ritonavir (LPVr) on the SARS-CoV-2 nasopharyngeal viral load in patients with mild to moderate COVID-19 infectio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
91a0e4e5-1891-5fba-a956-160b9f6ca8e5
DOI
10.2139/ssrn.4243701
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Therapeutic Combinations in Mild or Moderate COVID-19 to Reduce Nasopharyngeal Carriage of SARS-CoV-2 and Prevent Severe COVID-19 in Côte D’Ivoire: A Pragmatic Phase IIb Randomized Controlled Clinical Trial. The ANRS COV01 INTENSE-COV TrialDOI 10.2139/ssrn.4243701
SARS-COV-2 nasopharyngeal viral load change in a multicenter randomized clinical trial comparing early therapies for COVID-19 in non-hospitalized adults with high risk of severe COVID-19 (the MONET TRIAL)Semantic proximity
SARS-COV-2 nasopharyngeal viral load change in a multicenter randomized clinical trial comparing early therapies for COVID-19 in non-hospitalized adults with high risk of severe COVID-19 (the MONET TRIAL)Semantic proximity
Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in EnglandSemantic proximity
A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir Vs Currently Used Therapy in Severe COVID-19 Adults. (COMVIVIR, clinicaltrials.gov NCT04475991)Semantic proximity
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.Semantic proximity
Actual Clinical Efficacy of Statin Therapy (Hmg-CoA Reductase Inhibitors) on the Course of SARS-Cov-2/COVID-19 Infection During the Domination Period of Alpha, Beta, Gamma and Delta VariantsSemantic proximity
How the clinical research community responded to the COVID-19 pandemic: An analysis of the COVID-19 clinical studies in ClinicalTrials.govSemantic proximity
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 community, highly vaccinated patients with high risk for severe disease: Evidence that both antivirals reduce the risk for disease progression and deathSemantic proximity
REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 ResultsSemantic proximity
Effectiveness of Molnupiravir for the Treatment of COVID-19: A Systematic Literature Review of Real-World Observational StudiesSemantic proximity
Effectiveness of Molnupiravir for the Treatment of COVID-19: A Systematic Literature Review of Real-World Observational StudiesSemantic proximity
A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial.Semantic proximity
Select a neighboring publication to make it the new centre.